ATRAID
-
ATRAID Gene: Comprehensive Overview
Introduction
The ATRAID gene, also known as All-Trans Retinoic Acid Induced Differentiation Factor, is a protein-coding gene located on Chromosome 2 (2p23.3). It plays a pivotal role in skeletal development, cellular signaling, and the body‘s response to specific therapeutic drugs.
Molecular & Biological Functions
1. Bone Development and Mineralization
ATRAID is a key regulator of osteoblast differentiation. It promotes the process of bone formation and is essential for terminal mineralization, which ensures bone density and strength.
2. Pharmacogenomics: Bisphosphonate Transport
A critical function of ATRAID is its involvement in the transport of Nitrogen-containing Bisphosphonates (N-BPs). Within osteoclasts, ATRAID forms a transporter complex that enables these molecules to be released into the cytosol from lysosomes, allowing the medication to effectively inhibit bone resorption.
3. Cell Cycle Control and Apoptosis
As part of the ATRA (All-Trans Retinoic Acid) signaling pathway, ATRAID acts as a tumor suppressor by:
-
Inhibiting the expression of CCND1 (Cyclin D1).
-
Inducing cell cycle arrest.
-
Modulating apoptosis (programmed cell death), particularly in hematopoietic cells.
Clinical Significance and Associated Diseases
Genetic variants in ATRAID are linked to several hereditary conditions, primarily affecting ocular health and metabolic pathways:
-
Hereditary Cataracts: Including early-onset non-syndromic cataract, Cataract 13, and Cataract 38.
-
Lens Disorders: Isolated ectopia lentis (displacement of the lens).
-
Hyperferritinemia: Hereditary hyperferritinemia with congenital cataracts.
-
Oncology: Potential roles in cancer progression due to its influence on cell cycle regulation.
Gene Summary Table
Feature Specification Gene Symbol ATRAID Full Name All-Trans Retinoic Acid Induced Differentiation Factor Chromosomal Location 2p23.3 Protein Name Apoptosis-related protein 3 (APR-3) Aliases APR3, C2orf28, HSPC013, p18, PRO240 Genetic Testing & Diagnostics
WES Availability at MapmyGenome
Clinical analysis of the ATRAID gene is available through Whole Exome Sequencing (WES) at MapmyGenome. Our WES platform provides deep coverage of the protein-coding regions, allowing for the identification of pathogenic variants associated with hereditary cataracts and skeletal abnormalities. This comprehensive screening supports clinicians in personalized treatment planning and risk assessment.
-
